Prognostic impact of familial screening in dilated cardiomyopathy
- 1 September 2010
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 12 (9), 922-927
- https://doi.org/10.1093/eurjhf/hfq093
Abstract
Familial screening of patients with dilated cardiomyopathy (DCM) allows an early diagnosis of the disease in family members. It is unclear if familial forms (FDC) have a different long-term outcome compared with sporadic DCM. Our aim was to compare the long-term prognosis of FDC and sporadic forms in order to assess the role of familial screening. Between 1988 and 2007, 637 DCM patients were consecutively enrolled. Of these, 130 patients (20.4%) had FDC, including 82 (12.9%) probands and 48 (7.5%) non-proband FDC patients (NP-FDC), identified by family screening. We compared the 48 NP-FDC patients with a sample of 96 patients with sporadic DCM, who were randomly matched by year of enrolment in a 2:1 ratio. At enrolment the NP-FDC patients were younger (40 +/- 16 vs. 48 +/- 13 years, P = 0.002), less symptomatic [New York Heart Association, (NYHA) III-IV: 8 vs. 28%, P = 0.006], had higher left ventricular ejection fraction (35 +/- 10 vs. 30 +/- 9%, P = 0.005) and were less intensively treated with evidence-based drugs than the sporadic DCM patients. Survival free from heart transplant at 2, 5 and 10 years was 93, 91 and 82%, respectively, in NP-FDC patients compared with 86, 76 and 62% in sporadic forms (P = 0.04). After stratification for NYHA classes, no difference in survival was observed between sporadic and NP-FDC patients. Our study demonstrates that family screening can effectively identify DCM patients at an earlier stage of disease and can improve survival. The possibility of changing the prognosis of DCM needs to be verified in patients intensively treated with tailored medical treatment. Family screening should be recommended for all DCM patients.Keywords
This publication has 24 references indexed in Scilit:
- Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure – a subgroup analysis from the Trieste Cardiomyopathy RegistryJournal of Cardiovascular Medicine, 2009
- Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseasesEuropean Heart Journal, 2007
- Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practiceEuropean Journal of Heart Failure, 2005
- The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart FailureNew England Journal of Medicine, 2005
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the CommunityCirculation, 2003
- Metoprolol in dilated cardiomyopathy: Is it possible toidentify factors predictive of improvement?Journal of Cardiac Failure, 1996
- Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of CardiomyopathiesCirculation, 1996
- Changing mortality in dilated cardiomyopathyHeart, 1994
- The Clinical Course of Idiopathic Dilated CardiomyopathyAnnals of Internal Medicine, 1992